The Liposome Co. Inc. has reported positive responses in anongoing Phase II study of its liposomal doxorubicin in womenwith metastatic breast cancer.
According to an abstract in the Proceedings of the AmericanSociety of Clinical Oncology, published for the May ASCOmeeting in San Diego, interim results indicated that nine of 17women treated with TLC D-99 had partial or completeresponses to the drug.
One patient had a complete response, defined as no signs oftumors for at least 30 days. The other eight had partialresponses, or a 50 percent reduction in tumors for at least 30days.
No patients experienced clinically significant cardiotoxicity, oneof the major side effects of doxorubicin, and severegastrointestinal effects were uncommon. As expected,neutropenia was the dose-limiting toxicity.
The Princeton, N.J., company (NASDAQ:LIPO) has licensed TLCD-99 worldwide to Pfizer Inc. Liposome shares gained $1.38 to$10.88 on Tuesday.
Liposome Technology Inc. (NASDAQ:LTIZ) is also developing aliposomal form of doxorubicin, which in January began PhaseI/II trials in patients with Kaposi's sarcoma.
Vestar Inc. has put on hold development of its liposomalversion of the drug in favor of work on its other anthracyclinedrug, DaunoXome daunorubicin, said Dr. Michael Ross, executivevice president for medical and regulatory affairs. That drug isfinishing Phase II trials in Kaposi's sarcoma patients.
DaunoXome data from one Phase II center, presented at theAmerican Society of Hematology meeting in Denver lastDecember, showed a 60 percent response rate in patients, withno gastrointestinal effects or cardiotoxicity, and mildneutropenia, Ross said.
Vestar (NASDAQ:VSTR) has completed Phase I trials in solidtumors and found no toxicity. That data will also be reported atthe ASCO meeting. -- Karen Bernstein
(c) 1997 American Health Consultants. All rights reserved.